Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)

被引：0
|
作者：
Cheng, C-Y. [1 ]
Su, P-J. [2 ]
Chang, K-C. [3 ]
Tsai, T-C. [3 ]
Chen, H-Y. [3 ]
Deng, S-T. [3 ]
Chang, W-C. [2 ]
机构：
[1] Linkou Chang Gung Mem Hosp, Chang Gung Med Fdn, Pharm, Taoyuan, Taiwan
[2] Chang Gung Mem Hosp, Med Oncol, Taoyuan, Taiwan
[3] Chang Gung Mem Hosp, Pharm, Taoyuan, Taiwan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
    Maillet, Denis
    Corbaux, Pauline
    Stelmes, Jean-Jacques
    Dalle, Stephane
    Locatelli-Sanchez, Myriam
    Perier-Muzet, Marie
    Duruisseaux, Michael
    Kiakouama-Maleka, Lize
    Freyer, Gilles
    Boespflug, Amlie
    Peron, Julien
    EUROPEAN JOURNAL OF CANCER, 2020, 132 : 61 - 70
  • [2] Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs)
    Durbin, Sienna
    Zubiri, Leyre
    Perlman, Katherine
    Molina, Gabriel
    Jacoby, Ted
    Shah, Nishi
    Reynolds, Kerry Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Pancreatic adverse events in patients treated with immune checkpoint inhibitors
    Hana, Caroline
    Rehman, Tauseef
    Park, Kyeeun
    Uribe, Carlos Carracedo
    Aung, Pyi Phyo
    Hunis, Brian
    Salzberg, Matthew
    Zikria, Jennifer
    Hussein, Atif
    JGH OPEN, 2023, 7 (03): : 204 - 207
  • [4] Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
    Riudavets Melia, M.
    Gabriela Sullivan, I.
    Barba Joaquin, A.
    Anguera Palacios, G.
    del Carpio, L. P.
    Molto Valiente, C.
    Camacho Arellano, S. D.
    Moron Asensio, S.
    Gomila Pons, P.
    Andres Granyo, M.
    Castillo Villegas, D.
    Facundo Molas, C.
    Garcia Planella, E.
    Gonzalez Blanco, C.
    Barnadas Molins, A.
    Gich Saladich, I.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 509 - 509
  • [5] Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).
    Vitale, Nuzzo Pier
    Pond, Gregory Russell
    Abou Alaiwi, Sarah
    Nassar, Amin
    Flippot, Ronan
    Choueiri, Toni K.
    Harshman, Lauren Christine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] The association between HALP score and survival in patients treated with immune checkpoint inhibitors
    Sahin, Taha Koray
    Guven, Deniz Can
    Durukan, Mert
    Bas, Onur
    Kaygusuz, Yunus
    Arik, Zafer
    Dizdar, Omer
    Erman, Mustafa
    Yalcin, Suayib
    Aksoy, Sercan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (01) : 81 - 89
  • [7] Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis
    Euvrard, Romain
    Robert, Marie
    Mainbourg, Sabine
    Dalle, Stephane
    Lega, Jean-Christophe
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2024, 38 (02) : 369 - 379
  • [8] Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Paderi, Agnese
    Giorgione, Roberta
    Giommoni, Elisa
    Mela, Marinella Micol
    Rossi, Virginia
    Doni, Laura
    Minervini, Andrea
    Carini, Marco
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    CANCERS, 2021, 13 (04) : 1 - 11
  • [9] Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Cook, Sarah
    Samuel, Vanessa
    Meyers, Daniel E.
    Stukalin, Igor
    Litt, Ishjot
    Sangha, Randeep
    Morris, Don G.
    Heng, Daniel Y. C.
    Pabani, Aliyah
    Dean, Michelle
    Navani, Vishal
    JAMA NETWORK OPEN, 2024, 7 (01) : E2352302
  • [10] Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.
    Grizzi, Giulia
    Petrelli, Fausto
    Ghidini, Michele
    Ghidini, Antonio
    Ratti, Margherita
    Panni, Stefano
    Cabiddu, Mary
    Ghilardi, Mara
    Borgonovo, Karen
    Parati, Maria Chiara
    Barni, Sandro
    Tomasello, Gianluca
    Passalacqua, Rodolfo
    Berruti, Alfredo
    Brighenti, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345